The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study
1. 请及时下载文件确认是否正确, 系统将在 2026-03-16 16:46:38 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
E Niv, T Naftali, R Hallak, N Vaisman
Clinical nutrition, 2005
Elsevier
BACKGROUND: It was suggested that the intestinal microflora may play a role in the pathogenesis of irritable bowel syndrome (IBS). Probiotics may ease symptoms in IBS patients by changing gut microflora, reducing mucosal inflammation and exerting antibacterial effects. AIM: To assess the short-and long-term effects of Lactobacillus reuteri administration on clinical symptoms of IBS. METHODS: This is a double blind, placebo-controlled 6-month trial. Subjects consumed 1× 108cfu/tablet twice a day. The clinical …
